Detalhe da pesquisa
1.
Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
Br J Dermatol
; 182(6): e186-e209, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32476149